We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Abbott to Gain Leadership in POC Diagnostics upon Acquisition of Alere

By LabMedica International staff writers
Posted on 04 Feb 2016
Print article
Abbott Inc. (Abbott Park, IL, USA) and Alere Inc. (Waltham, MA, USA) have reached a definitive agreement under which Abbott will pay an equity value of about USD 5.8 billion to acquire Alere. Once the transaction is completed, Abbott will become leading diagnostics provider of point-of-care (POC) testing. Abbott’s diagnostics presence and leadership will be significantly advanced as Alere's complementary technologies will help Abbott provide better care for patients by providing fast, accurate, and actionable medical information to help guide decision-making.

Under the terms of the agreement, Abbott will pay USD 56 per common share at a total expected equity value of USD 5.8 billion. The transaction will be immediately accretive to Abbott's ongoing earnings-per-share upon close and significantly accretive thereafter. Alere will become a subsidiary of Abbott.

The combined business will offer the broadest POC menu of infectious disease, molecular, cardiometabolic, and toxicology testing, expanding Abbott's platforms to include benchtop and rapid strip tests. Abbott will better serve an expansive customer base while also accelerating innovation.

Abbott will provide new, flexible, cost-effective, high-quality products to help meet growing demand in both in-patient and out-patient settings. Alere's complementary portfolio will provide Abbott access to new product applications, channels, and geographies, including entry into fast-growing outlets such as doctors' offices, clinics, pharmacies, and at-home testing. Alere has a large presence in the US and a growing presence in key international markets, where Abbott's capabilities and infrastructure will drive accelerated growth of Alere's portfolio.

"The combination of Alere and Abbott will create the world's premier POC testing business," said Miles D. White, chairman and CEO, Abbott, "We want to offer our customers the best and broadest diagnostics solutions. Alere helps us do that."

This “marks an exciting and transformative milestone for Alere, and one that provides an immediate benefit for our stockholders," said Namal Nawana, president and CEO, Alere, "Our leading platforms and global presence in POC diagnostics, combined with Abbott's broad portfolio of market-leading products, will accelerate our shared goal of improving patient care. I'd like to thank our global workforce of nearly 10,000 employees whose hard work and dedication has enabled Alere to contribute to improved patient outcomes throughout the world."

Related Links:

Abbott
Alere


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Reagent Reservoirs
Reagent Reservoirs

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.